The falling share price just reflects uncertainty of the...

The falling share price just reflects uncertainty of the restrictions will imposed on drug prescriptions. Sales may slow and less than expected. On the other hand, may not all too bad, FDA still allow to sale, no one will be sure how big the market for people really needed. Upside is that Axiron starts selling more countries around world, sales may not too bad. fundamentally no much has been changed. I think who in ACR should already fact in today's announcement. That is why management did not make announcement for it. Share price may suffer for a while, but wait the sales figures out for next two reports, then can make our mind to stay or exit.